EL 0219-2190 Part B

Stipend and Dates

Up to $21,600. Multiple payments

Note: All dates and times are tentative and may change	Cohort B2
Local patients only - requires proof of local residence (approx. 60-75 miles) with either ID or recent bill. *Be sure your address is correct when scheduling your appointment online.	Patients out of area will be cancelled.
Day -3 Admit	Oct 16, 2022 Sun
Day 4 Discharge (a payment within 10 business days after completing visit)	Oct 22, 2022 Sat
Day 8 Outpatient visit	Oct 26 Wed
Day 15 Outpatient visit	Nov 02 Wed
Day 22 Outpatient visit	Nov 09 Wed
Day 28 Admit	Nov 15, 2022 Tue
Day 29 Discharge	Nov 16, 2022 Wed
Day 36 Outpatient visit (a payment within 10 business days after completing visit)	Nov 23 Wed
Day 43 Outpatient visit	Nov 30 Wed
Day 50 Outpatient visit	Dec 07 Wed
Day 56 Admit	Dec 13, 2022 Tue
Day 57 Discharge	Dec 14, 2022 Wed
Day 64 Outpatient visit	Dec 21 Wed
Day 71 Outpatient visit	Dec 28 Wed
Day 77 Admit	Jan 03, 2023 Tue
Day 81 Discharge (a payment within 10 business days after completing visit)	Jan 07, 2023 Sat
Day 85 Outpatient visit	Jan 11 Wed
Day 99 Outpatient visit	Jan 25 Wed
Day 120 Outpatient visit	Feb 15 Wed
Day 153 End of Study visit (a payment within 10 business days after completing visit)	Mar 20, 2023 Mon

 

Click here to make an appointment EL 0219-2190 Part B

Or call 210-225-5437 for more information

Study Criteria

Overweight Males and Females (non-childbearing)

Age:  21-65

BMI:  27-39.9 kg/m2    

Study Information

Indication: The investigational drug is being developed as a possible treatment for weight management.

Route of Administration: Subcutaneous (under the skin) injection

Washout from previous study:    Have not participated, within the last 30 days or 5 half-lives (whichever is longer), in a clinical study involving an investigational product or are currently participating in a clinical study.

Males who are sexually active and whose partners are females of childbearing potential must agree to remain abstinent or must use condoms throughout the study and for 24 weeks after the last dose of study drug.  

Males should not donate sperm throughout the study and for 24 weeks after the last dose of study drug.

Females must not be able to have children (non-childbearing):

• Hysterectomy (removal of uterus), bilateral salpingectomy (removal of both Fallopian tubes), bilateral oophorectomy (removal of both ovaries)
• Post-Menopausal more than one year prior to study entry (stopped having monthly menstrual periods more than one year ago)

Study Reminders

• 8 hours fasting is required for lab work (only water is allowed)
• If taking medications, bring them to your screening appointment (including prescription, over the counter, herbal supplements and vitamins)
• Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a valid government issued identification card such as a driver's license, state issued ID card or passport.  You will be required to show this same photo ID at all study visits
• Arrive 30 minutes before your appointment to complete paper work.